Pharmacosmos Therapeutics Inc.

▎药明康德内容团队编辑 诺奖得主联合创建，新锐致力开发潜在“first-in-class”免疫疗法 Valora Therapeutics今日宣布成功完成3000万美元的种子轮融资，该公司致力于利用其糖基-免疫检查点技术平台变革免疫疗法开发。 Valora的AbLec平台（抗体-凝集素嵌合体，antibody-lectin chimera）预计将为恢复免疫系统的正常功能提供全新视角。通过精准靶向细胞表面的特定糖分子，AbLec平台能够调节糖基-免疫检查点，这是一种机体免疫反应的重要调控机制。这一创新方法在肿瘤学、自身免疫性疾病及其他治疗领域开发潜在“first-in-class”和“best-in-class”疗法方面具有巨大潜力。 这一技术来自斯坦福大学，基于诺贝尔化学奖得主、糖生物学领域先驱Carolyn Bertozzi博士实验室的开创性研究成果，以及麻省理工学院生物工程与化学工程助理教授Jessica Stark博士的相关研究工作。Bertozzi博士和Stark博士均为Valora公司的科学创始人和顾问。 体内制造CAR-T疗法，诺华达成研发合作 Vyriad公司今日宣布与诺华（Novartis）达成一项战略合作，共同发现和开发在患者体内制造的嵌合抗原受体（CAR）-T细胞疗法。此次合作将结合Vyriad的靶向慢病毒载体平台与诺华在细胞疗法创新方面的专业知识。双方将专注于发现和开发体内CAR-T细胞疗法候选药物，这些药物将由诺华推进至临床开发阶段。根据协议，Vyriad将获得首付款和里程碑付款。 凭借其病毒载体工程化专业技术，Vyriad开发出一种慢病毒递送系统，该系统有潜力将转基因在体内特异性递送到T细胞中，从而在体内将其重新编程为潜在的患者治疗方案。这一技术让将表达嵌合抗原受体的转基因在患者体内靶向递送到T细胞中成为可能。 支持初创公司开发抗癌疗法，孵化器完成7000万美元融资 Jupiter Bioventures是一家专注于打造以科学驱动的创新疗法公司的生物技术孵化器。该公司今日宣布完成7000万美元的首轮融资。本次融资将用于支持8至10家初创公司，这些公司专注于解决癌症及其他受癌症生物学启发的疾病领域中的未满足需求。 Jupiter由两位拥有数十年经验的生物技术企业家创立：Nathaniel David博士曾共同创立Syrrx、Achaogen、Kythera Biopharmaceuticals和UNITY Biotechnology；Norman Sharpless博士曾担任美国国家癌症研究所主任和美国FDA代理局长，目前是美国国家医学院院士，并共同创立了G1 Therapeutics。两位创始人领导的公司已累计推出5款获批药物，完成4次IPO和3次企业收购。 Jupiter基于“科学优先”模式的理念，以一套商业和科学标准评估潜在项目，并通过部署团队和少量种子资金来通过实验验证研发项目的核心理念。最具潜力的研发项目将获得来自Jupiter及非Jupiter投资者的进一步投资，发展为独立运营的生物技术公司，并拥有充足资金以在人体试验中获得概念验证。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放 参考资料： [1] Industry Veterans Announce Jupiter Bioventures, a Biotechnology Venture Foundry that Turns Novel Science into Transformational Companies. Retrieved November 20, 2024, from https://www.globenewswire.com/news-release/2024/11/19/2983529/0/en/Industry-Veterans-Announce-Jupiter-Bioventures-a-Biotechnology-Venture-Foundry-that-Turns-Novel-Science-into-Transformational-Companies.html [2] Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies. Retrieved November 20, 2024, from https://vyriad.com/newsevents/vyriad-announces-strategic-collaboration-with-novartis-to-develop-in-vivo-car-t-cell-therapies/ [3] Valora Therapeutics Raises $30 Million Seed Financing from Top Investors to Transform Immunotherapy with a Novel Glyco-immune Checkpoint Platform. Retrieved November 20, 2024, from https://www.businesswire.com/news/home/20241120665932/en/Valora-Therapeutics-Raises-30-Million-Seed-Financing-from-Top-Investors-to-Transform-Immunotherapy-with-a-Novel-Glyco-immune-Checkpoint-Platform 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新

Co-Founders Nathaniel "Ned" David, PhD, and Norman "Ned" Sharpless, MD, will apply decades of experience to establish a scalable biotech foundry $70 million raised to evaluate, found and operate biotech companies pursuing unmet needs in cancer and disease areas in which cancer biology provides insight Founding investors Mission BioCapital and Mayo Clinic joined by other longtime life science investors SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Jupiter Bioventures ("Jupiter"), a biotechnology venture foundry that builds bold, science-driven therapeutics companies, today announced the closing of a $70 million initial financing. The syndicate includes co-founding investors Mission BioCapital and Mayo Clinic. New investors include Alexandria Venture Investments, Bioventure Partners, Cedars-Sinai Intellectual Property Company, CU Healthcare Innovation Fund, Eric Ball, Eshelman Ventures, Fox Ventures, The Brent and Julie Callinicos Trust and Vault Fund. Proceeds from this financing will advance eight to ten companies developing therapeutics to treat cancer and other diseases where cancer biology provides insight. Jupiter was founded by two biotech entrepreneurs with decades of experience forming and operating biotech ventures: Nathaniel “Ned” David, PhD, previously co-founded Syrrx (acquired by Takeda), Achaogen, Kythera Biopharmaceuticals (acquired by Allergan) and UNITY Biotechnology. Norman “Ned” Sharpless, MD, was previously Director of both the National Cancer Institute and UNC’s Lineberger Comprehensive Cancer Center, Acting Commissioner of the US Food and Drug Administration, is currently a Member of the National Academy of Medicine and was a co-founder of G1 Therapeutics (acquired by Pharmacosmos). Between them, Drs. Sharpless and David’s previous companies have generated five approved medicines, four IPOs and three corporate acquisitions. Jupiter is built on the premise that a “science first” model can return higher multiples on invested capital than conventional venture funds. Jupiter starts by evaluating potential projects—dubbed “Moons”—using a set of business and scientific criteria. Jupiter then deploys a team and small amounts of seed capital to secure intellectual property and experimentally validate the core idea. The most promising Moons receive additional investment from both Jupiter and non-Jupiter investors to become freestanding, high-value biotech companies with sufficient capital to demonstrate proof-of-concept in humans. “We love bold science, but we hate risk,” said Jupiter co-founder Dr. Ned David. “By experimentally confirming the science first, we kill bad projects early, so we can focus on the winners.” “Ned and I have been building companies and medicines for decades,” said Jupiter co-founder Dr. Ned Sharpless. “We built Jupiter to identify the next set of world-changing ideas and efficiently remove the risks that stand in their way. It is our mission to build companies that improve patient lives.” “Mayo Clinic is committed to producing meaningful, effective change that transforms health and medicine. Clinical excellence requires continual discovery, translation and innovation. We’re eager to see what innovations show promise through this unique biotech model,” said Vijay Shah, MD, Kinney Executive Dean for Research at Mayo Clinic. “Ned and Ned are among the most talented drug hunters and entrepreneurs we’ve worked with. We’re thrilled to work with Jupiter in scaling their approach to build transformational therapeutics companies,” said Zach Collins, PhD, Partner at Mission BioCapital. Coincident with the financing, Jupiter announced that Fred Eshelman, the founder of Eshelman Ventures LLC, an investment company primarily interested in private healthcare companies, will join the Board of Directors. Dr. Eshelman is a successful life science entrepreneur who founded and served as CEO and Executive Chairman of Pharmaceutical Product Development before the sale of the company to private equity interests. He also brings significant board experience as Founding Chairman and largest shareholder of Furiex Pharmaceuticals, Chairman of The Medicines Company and board member of Valeant Pharmaceuticals. “Jupiter’s approach to biotechnology company formation is a truly disruptive innovation, and I’m excited to be part of it,” said Dr. Eshelman. “It will be a pleasure to work collaboratively with Ned David, Ned Sharpless and my fellow directors to execute a science-first strategy to bring groundbreaking therapeutic breakthroughs to patients.” “Jupiter’s strategic mission aligns with Cedars-Sinai’s approach to technology, commercialization and research to improve patient outcomes and advance healthcare solutions,” said James Laur, JD, Chief Executive, Intellectual Property & Health Ventures at Cedars-Sinai. Nirdesh K. Gupta, PhD, managing partner of the Cedars-Sinai Intellectual Property Company, will join the Board of Directors at Jupiter. Dr. Gupta has overseen multiple drug development projects resulting in clinical candidates that are now in late-stage trials in oncology, immune-mediated conditions and rare diseases. This work has resulted in the formation of several companies with significant financial exits, including Prometheus Biosciences. Dr. Gupta expressed, “We look forward to forging a productive relationship with the team through this foundry and to their science-first approach which has worked very well for us all along.” About Jupiter BioventuresJupiter Bioventures (“Jupiter”) is a biotechnology venture foundry that builds bold, science-driven startups from the ground up. Jupiter creates opportunities at scale by validating groundbreaking science quickly to produce de-risked venture-stage companies with therapeutic candidates. Partnering with world-leading scientists, Jupiter supports and manages a system of “Moons”—its portfolio of start-up companies. These Moons address unmet needs in cancer and related diseases. Jupiter’s managing directors are proven serial entrepreneurs with decades of expertise in company-building, strategic transactions and high-impact leadership. For more information, visit www.jupiter.bio. Media Contact:Janine McCargo 6 DegreesPhone +1 (646) 528-4034Email: jmccargo@6degreespr.com

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced the appointment of Norman E. “Ned” Sharpless, MD, to the Company’s Board of Directors as an independent director. Dr. Sharpless is a physician, scientist and entrepreneur who has led tremendous progress in cancer research and care serving in several leadership roles, including Director of the National Cancer Institute (NCI) and Acting Commissioner of the US Food and Drug Administration (FDA). “We’re thrilled to welcome Ned, a distinguished oncologist, accomplished scientist and seasoned public servant, to our Board of Directors,” said Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer and Co-Founder of Incyclix Bio. “Ned brings unparalleled oncology expertise and experience to our Board at this important point in our growth. Ned’s passion and commitment to innovating cancer care and scientific prowess, particularly in cell cycle biology, will be invaluable as we race to bring INX-315 to patients.” “I have dedicated my career to improving the lives of people affected by cancer,” said Dr. Sharpless. “Incyclix has made exciting progress investigating the potential of its CDK2 inhibitor, INX-315, to provide treatment for patients with advanced and resistant cancer. I look forward to working with Incyclix’s experienced board and leadership team to bring this important novel treatment option to patients in need.” Dr. Sharpless is a physician, scientist, entrepreneur and former federal official, serving as Director of the National Cancer Institute from 2017 to 2022, and as Acting Commissioner of the FDA in 2019. As a federal official, he led multiple research initiatives spanning cellular immunotherapy, early cancer detection, global oncology and the use of artificial intelligence and machine learning to improve outcomes for patients affected by cancer. Prior to government, Dr. Sharpless was the Wellcome Distinguished Professor of Medicine and Director of the Lineberger Comprehensive Cancer Center at the University of North Carolina (UNC) School of Medicine. He is on the boards Karius Inc., Nucleus Radiopharma, the Eshelman Institute for Innovation, the CEO Roundtable on Cancer and the American Cancer Society; and is the co-Founder and Managing Director of Jupiter BioVentures. He was founder and board member of G1 Therapeutics, which developed the FDA-approved medicine Cosela (Trilaciclib), used to prevent chemotherapy toxicity. He is the Professor of Cancer Policy and Innovation at the UNC School of Medicine, and is a member of the American Association for Cancer Research Academy, the Association of American Physicians, the American Society for Clinical Investigation and the National Academy of Medicine. He received an MD from the UNC School of Medicine, followed by an internal medicine residency at the Massachusetts General Hospital and a hematology/oncology fellowship at the Dana-Farber/Partners Cancer Care, both of Harvard Medical School. About Incyclix Bio Incyclix Bio is a next-generation cell cycle control company advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development. For more information, visit incyclixbio.com. Media ContactTony Plohoros908-591-2839tplohoros@6degreespr.com